Unicycive Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Unicycive Therapeutics

10/08/2026 14:43

Unicycive Therapeutics Inc UNCY.OQ UNCY.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Unicycive Therapeutics Inc is for a loss of 34 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Unicycive Therapeutics Inc is $30.00, about 491.7% above its last closing price of $5.07
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.63
-0.48
-0.54
Missed
-13.5
Dec. 31 2026
-0.47
-0.82
Missed
-73
Sep. 30 2025
-0.54
-0.56
-0.33
Beat
40.7​
Jun. 30 2025
-0.74
-0.74
-0.52
Beat
29.7
​​Mar. 31 2025
-0.67
-1.13
-0.50
Beat
55.9
Dec. 31 2024
-0.90
-2.60
Missed
-188.9​
Sep. 30 2024
-2.00
-1.52
-0.50
Beat
67
Jun. 30 2024
-2.05
-1.92
-1.50
Beat
21.7
This summary was machine generated August 10 at 13:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)